Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since Aug 26 · below the Ichimoku cloud · RSI 39 · MACD below its signal
None of the 29 investors followed here reported a position in NDRA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NDRA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 1, 2026 | Tokman Alexander YChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 26.9K | — |
| Mar 1, 2026 | Jacroux RichardChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 13.5K | — |
| Jan 20, 2026 | Digiandomenico AnthonyDirector | Stock Award(Grant) at price 0.00 per share. | 60.3K | — |
| Jan 20, 2026 | Tokman Alexander YChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Jan 20, 2026 | Harsh Michael JohnDirector | Stock Award(Grant) at price 0.00 per share. | 60.3K | — |
| Jan 20, 2026 | Basenese Louis J.Director | Stock Award(Grant) at price 0.00 per share. | 60.3K | — |
| Jan 20, 2026 | Jacroux RichardChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Oct 9, 2025 | Digiandomenico AnthonyDirector | Stock Award(Grant) at price 7.06 per share. | 70.8K | $500.00K |
| Jun 10, 2025 | Digiandomenico AnthonyDirector | Stock Award(Grant) at price 0.00 per share. | 5.4K | — |
| Jun 10, 2025 | Harsh Michael JohnDirector | Stock Award(Grant) at price 0.00 per share. | 5.4K | — |
| Jun 10, 2025 | Basenese Louis J.Director | Stock Award(Grant) at price 0.00 per share. | 5.4K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.1 | 9.2 | 12.0 | 4.7 | 12.9 | -3.1 | -11.8 | 6.5 | 19.1 | -15.4 | +11.3% | ||
| 2025 | -23.2 | -10.0 | -5.3 | 46.6 | -44.3 | 4.8 | 50.4 | -22.6 | 31.6 | -2.4 | 12.6 | -23.4 | −27.6% |
| 2024 | -50.5 | 6.7 | -48.2 | -51.2 | -4.9 | -63.9 | -18.6 | -90.3 | -47.5 | 25.4 | -35.3 | 9.6 | −99.8% |
| 2023 | -1.5 | -2.7 | -41.3 | -30.1 | -8.1 | -4.8 | -11.4 | -5.6 | -5.1 | -11.3 | 0.7 | 113.7 | −47.9% |
| 2022 | -13.3 | -28.7 | -8.9 | -33.6 | -11.2 | 1.3 | 18.0 | 6.2 | 4.8 | -24.8 | -22.6 | 14.3 | −70.6% |
| 2021 | 153.3 | 31.6 | 4.0 | -7.7 | -11.7 | 2.8 | -17.4 | 5.6 | -8.9 | -8.7 | -39.7 | -27.3 | −7.7% |
| 2020 | -13.7 | -24.2 | -34.3 | 7.5 | 18.6 | 4.6 | 2.4 | -16.8 | -10.7 | -6.0 | 19.3 | -8.6 | −55.4% |
| 2019 | 40.0 | -21.4 | 0.6 | -7.8 | -23.5 | 46.2 | -12.3 | 13.3 | -37.6 | -0.3 | -20.6 | 100.2 | +12.0% |
| 2018 | -27.8 | -13.4 | -14.5 | -4.2 | -24.1 | 34.9 | -2.4 | 4.8 | 17.2 | 76.5 | -38.7 | -54.7 | −69.1% |
| 2017 | -12.8 | -4.4 | -2.2 | -27.7 | 56.5 | 35.0 | +24.6% |
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.